Pharmacology Quiz: Diuretics In Heart Failure

20 questions · exam conditions

0:00

Diuretics In Heart FailureQuestion 1 of 20

A 70-year-old male with HFrEF (LVEF 30%) is assessed in clinic. He is euvolemic on furosemide 40 mg daily, lisinopril 20 mg daily, and carvedilol 25 mg BID. His serum K+ is 4.5 mEq/L and SCr is 1.1 mg/dL. According to current evidence-based guidelines, which medication should be added next to improve mortality?

An SGLT2 inhibitor, such as dapagliflozin.

A higher dose of furosemide, up to 80 mg daily.

Hydralazine and isosorbide dinitrate.

A calcium channel blocker, such as amlodipine.

← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Diuretics In Heart Failure

Practice Diuretics In Heart Failure in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Diuretics In Heart Failure, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

An SGLT2 inhibitor, such as dapagliflozin. (correct answer)
A higher dose of furosemide, up to 80 mg daily.
Hydralazine and isosorbide dinitrate.
A calcium channel blocker, such as amlodipine.

Explanation: This patient is on two of the foundational pillars of HFrEF therapy (ACEi and beta-blocker). The addition of a mineralocorticoid receptor antagonist (MRA) and an SGLT2 inhibitor are the next steps to complete the 'four pillars' of guideline-directed medical therapy. Given the options, adding an SGLT2 inhibitor like dapagliflozin or empagliflozin is a critical next step shown to reduce mortality and hospitalizations, and his renal function is adequate. While an MRA would also be appropriate, it is not offered as a distinct choice. Increasing furosemide (B) is incorrect as he is euvolemic and diuretics do not improve mortality. Hydralazine/isosorbide (C) is reserved for specific patient populations. Amlodipine (D) is not a first-line HFrEF medication.

Question 2

A 70-year-old female with a new diagnosis of heart failure with preserved ejection fraction (HFpEF) presents with mild bibasilar crackles and 1+ pedal edema. Her blood pressure is 155/88 mmHg and her eGFR is 70 mL/min/1.73m². Which agent is the most appropriate initial choice for management of her volume and blood pressure?

Furosemide
Bumetanide
Spironolactone
Chlorthalidone (correct answer)

Explanation: In patients with HFpEF, hypertension is a common comorbidity and a key treatment target. For mild volume overload in the setting of hypertension and preserved renal function, a thiazide-type diuretic like chlorthalidone is an excellent first-line choice. It effectively controls volume, provides sustained blood pressure reduction, and has demonstrated cardiovascular benefits in hypertension trials. Loop diuretics like furosemide (A) or bumetanide (B) are generally reserved for more significant volume overload or when GFR is low. Spironolactone (C) is used in selected HFpEF patients but is not the first choice for initial volume and BP management.

Question 3

A 67-year-old patient with end-stage HFrEF and severe cardiorenal syndrome (eGFR < 15 mL/min/1.73m²) is admitted with anasarca and pulmonary edema. He is refractory to a continuous infusion of furosemide at 40 mg/hr plus IV chlorothiazide. He remains oliguric and severely congested. What is the most appropriate next step for volume management?

Consult nephrology for initiation of ultrafiltration. (correct answer)
Add high-dose oral spironolactone to the regimen.
Initiate a vasopressin antagonist such as tolvaptan.
Administer a large bolus of albumin followed by more furosemide.

Explanation: When you encounter a patient with severe heart failure and advanced kidney disease who's not responding to maximum diuretic therapy, you're dealing with diuretic resistance - a critical scenario requiring mechanical fluid removal. Answer A is correct because ultrafiltration is the definitive treatment for diuretic-refractory volume overload in patients with severe cardiorenal syndrome. When loop diuretics combined with thiazides fail at maximum doses, the nephron's ability to respond to pharmacologic intervention is exhausted. Ultrafiltration mechanically removes fluid regardless of kidney function, providing precise volume control without relying on residual nephron responsiveness. Answer B is wrong because spironolactone, while beneficial for heart failure outcomes, provides minimal diuretic effect and won't address acute volume overload. In severe kidney disease, it also poses significant hyperkalemia risk. Answer C is wrong because tolvaptan (vasopressin antagonist) causes free water diuresis but requires functioning kidneys to work. With an eGFR <15, there's insufficient nephron mass for meaningful response, and it won't remove the sodium and water causing this patient's anasarca. Answer D is wrong because albumin-furosemide combinations work by improving diuretic delivery to the nephron, but this patient has already failed high-dose loop plus thiazide therapy, indicating the problem isn't drug delivery but lack of functional nephrons to respond. Key strategy: When you see "refractory to maximum medical therapy" plus severe kidney disease, think mechanical intervention. Diuretics need functioning nephrons - when those are gone, ultrafiltration becomes the only viable option for volume removal.

Question 4

A patient is being discharged from the hospital after an admission for ADHF. They are prescribed a flexible dose of furosemide, 40-80 mg daily. What is the most critical parameter for the patient to monitor at home to guide self-adjustment of their diuretic dose?

Daily blood pressure readings, taken at the same time each day.
Daily body weight, measured each morning after voiding and before eating. (correct answer)
Daily assessment of urine color to estimate hydration status.
Daily peripheral pulse rate, checking for significant changes.

Explanation: For patients with heart failure on diuretic therapy, daily weight monitoring is the most reliable and sensitive method for tracking fluid status. A weight gain of 2-3 pounds in a day or 5 pounds in a week often indicates fluid retention and may warrant an increase in the diuretic dose, as instructed by their physician. Blood pressure (A) is important to monitor but can be influenced by many factors and is a less direct measure of volume status than weight. Urine color (C) reflects hydration but not necessarily total body volume. Heart rate (D) is also a nonspecific indicator.

Question 5

A 72-year-old patient with HFrEF and stage 4 chronic kidney disease (estimated GFR of 25 mL/min/1.73m²) requires initiation of diuretic therapy for significant peripheral edema and pulmonary congestion. Which diuretic is the most appropriate agent to prescribe as monotherapy for effective volume removal in this patient?

Hydrochlorothiazide
Furosemide (correct answer)
Spironolactone
Chlorthalidone

Explanation: Loop diuretics, such as furosemide, are the diuretics of choice for managing volume overload in heart failure, especially in patients with significant renal impairment. Thiazide diuretics like hydrochlorothiazide (A) and chlorthalidone (D) lose their efficacy when the GFR falls below 30 mL/min/1.73m². Spironolactone (C), a potassium-sparing diuretic/mineralocorticoid receptor antagonist, is a weak diuretic and is primarily used for its mortality benefit in HFrEF, not for significant volume removal. It also carries a high risk of hyperkalemia in patients with advanced CKD.

Question 6

A 75-year-old female with acute decompensated heart failure (ADHF) is receiving a continuous infusion of IV furosemide at 10 mg/hr. Over the past 48 hours, her urine output has progressively declined despite titration of the infusion up to 20 mg/hr. She remains significantly volume overloaded with anasarca. Her serum creatinine has increased from 1.8 mg/dL to 2.2 mg/dL.

This clinical picture is most consistent with diuretic resistance. Which of the following strategies is most likely to restore effective diuresis?

Switching the infusion to an equipotent dose of bumetanide.
Administering a bolus of hypertonic saline prior to the next furosemide dose.
Adding a thiazide-type diuretic, such as oral metolazone or IV chlorothiazide. (correct answer)
Adding a potassium-sparing diuretic, such as spironolactone, to the regimen.

Explanation: The patient exhibits classic signs of diuretic resistance, where increasing doses of a loop diuretic yield a diminishing response. This is often due to hypertrophy of the distal convoluted tubule, which increases sodium reabsorption. The most effective strategy to overcome this is sequential nephron blockade: adding a thiazide-type diuretic (metolazone or chlorothiazide) to block sodium reabsorption distally, synergistically enhancing the effect of the loop diuretic. Switching to another loop diuretic (A) is unlikely to be effective as this is a class effect. Hypertonic saline (B) is an experimental strategy for diuretic resistance and not a standard first-line approach. Adding spironolactone (D) provides only weak diuresis and is not sufficient to overcome significant resistance, although it is used for its neurohormonal effects.

Question 7

A patient stabilized in the hospital for ADHF required 40 mg of IV furosemide twice daily for effective diuresis. The clinical team is planning for discharge. Assuming the patient's gut absorption is normal, what is the approximately bioequivalent total daily dose of oral furosemide?

40 mg daily
80 mg daily
120 mg daily
160 mg daily (correct answer)

Explanation: The oral bioavailability of furosemide is variable but typically estimated to be around 50%. Therefore, to convert from an IV dose to an oral dose, the IV dose is generally multiplied by two. The patient was receiving a total of 80 mg IV furosemide per day (40 mg x 2). The bioequivalent oral dose would be approximately 80 mg IV * 2 = 160 mg oral per day.

Question 8

A 79-year-old patient with ADHF and underlying chronic kidney disease is receiving rapid IV boluses of furosemide (120 mg over 5 minutes). The patient reports new-onset tinnitus and difficulty hearing. This adverse effect is most directly related to the:

total cumulative dose of furosemide administered during the admission.
co-administration of a beta-blocker, such as carvedilol.
rate of intravenous infusion of the furosemide dose. (correct answer)
synergistic effect with a concurrently administered ACE inhibitor.

Explanation: Ototoxicity is a known, dose-related adverse effect of loop diuretics. However, the risk is most significantly increased by the rapid rate of intravenous administration, which leads to high transient peak concentrations in the inner ear. Administering high doses over a longer period (e.g., as a slow infusion over 30-60 minutes) can mitigate this risk. While high total doses (A) and underlying renal dysfunction are risk factors, the rate of infusion is the most direct and modifiable cause of acute ototoxicity. Beta-blockers (B) and ACE inhibitors (D) are not associated with this interaction.

Question 9

A 62-year-old patient with chronic HFrEF managed with sacubitril/valsartan, carvedilol, and spironolactone presents for a follow-up visit. After a recent increase in his furosemide dose for mild edema, he complains of dizziness upon standing. His blood pressure is 95/60 mmHg with orthostasis. Labs show BUN 55 mg/dL and SCr 1.9 mg/dL (baseline SCr was 1.3 mg/dL). What is the most appropriate initial management step?

Administer a 500 mL bolus of normal saline.
Decrease the dose of carvedilol to improve blood pressure.
Temporarily hold or reduce the furosemide dose. (correct answer)
Discontinue the sacubitril/valsartan due to worsening renal function.

Explanation: The patient's symptoms (orthostatic dizziness), hypotension, and laboratory findings (elevated BUN/SCr ratio) are highly suggestive of volume depletion and pre-renal azotemia caused by over-diuresis. The most appropriate initial action is to address the root cause by holding or reducing the dose of the diuretic (furosemide). Administering saline (A) may be necessary but holding the diuretic is the first step. Decreasing carvedilol (B) or stopping sacubitril/valsartan (D) would be inappropriate as these are foundational, mortality-reducing therapies, and the problem is more likely iatrogenic volume depletion.

Question 10

A 68-year-old male with chronic heart failure with reduced ejection fraction (HFrEF) on a stable regimen of furosemide 40 mg twice daily, lisinopril, and carvedilol presents with a 7-lb (3.2 kg) weight gain over 5 days and worsening dyspnea on exertion. His renal function and electrolytes are at his baseline. He is hemodynamically stable. Which of the following is the most appropriate initial adjustment to his diuretic therapy?

Administer a one-time dose of intravenous (IV) furosemide 80 mg in the clinic.
Increase the oral furosemide dose to 80 mg twice daily and follow up in 2-3 days. (correct answer)
Add oral metolazone 2.5 mg daily to the current furosemide dose.
Switch from oral furosemide to an equivalent oral dose of bumetanide.

Explanation: The patient is experiencing mild-to-moderate volume overload on a stable diuretic dose, suggesting the need for dose escalation. The most appropriate initial step is to increase the dose of the existing oral loop diuretic. Increasing the oral furosemide to 80 mg BID doubles the dose and is a standard approach to regain euvolemia. Administering IV furosemide (A) is typically reserved for more severe, acute decompensation or if there is concern for poor gut absorption. Adding metolazone (C) induces sequential nephron blockade and is a powerful intervention reserved for significant diuretic resistance, not as a first step. Switching to another loop diuretic like bumetanide (D) is an option for patients with true furosemide allergy or poor furosemide bioavailability, but dose escalation of the current agent is the preferred initial strategy.

Question 11

A hospital protocol for assessing diuretic response in ADHF requires checking a laboratory value 1-2 hours after an initial IV bolus of furosemide. Which of the following measurements provides the most direct and rapid assessment of the pharmacodynamic effect at the renal tubule?

Spot urine sodium concentration. (correct answer)
Total urine output volume in the first hour.
Change in serum creatinine from baseline.
Change in serum B-type natriuretic peptide (BNP).

Explanation: When evaluating diuretic effectiveness in acute decompensated heart failure (ADHF), you need to assess the direct pharmacodynamic effect at the site of action—the renal tubules. Furosemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing sodium reabsorption and causing natriuresis. Spot urine sodium concentration (A) provides the most direct and rapid measurement of this tubular effect. Within 1-2 hours of furosemide administration, you can directly quantify how much sodium is being excreted in the urine. A urine sodium >50-70 mEq/L typically indicates adequate diuretic response, while lower values suggest diuretic resistance requiring dose adjustment or alternative strategies. Total urine output volume (B) is misleading because patients can produce large volumes of dilute urine without significant sodium loss, which won't improve volume overload. The goal isn't just water removal—it's sodium and fluid removal together. Change in serum creatinine (C) is too slow and indirect. Creatinine changes take 24-48 hours to reflect alterations in kidney function, and modest increases are actually expected with effective diuresis as intravascular volume contracts. Change in BNP (D) reflects overall cardiac stress and volume status but responds much more slowly than the direct tubular effects of furosemide. BNP changes occur over days, not hours. For pharmacology exams, remember that when assessing drug effects, the most direct measurement at the site of action is usually the best answer. Spot urine sodium directly reflects loop diuretic activity at the nephron level.

Question 12

A patient with advanced decompensated heart failure, significant ascites, and anasarca is demonstrating poor response to high-dose IV loop diuretics. In addition to renal tubular hypertrophy, which other patient-specific factor is most likely to be contributing to this profound diuretic resistance?

Elevated serum B-type natriuretic peptide (BNP).
A low left ventricular ejection fraction of 15%.
Hypoalbuminemia with a serum albumin of 2.1 g/dL. (correct answer)
Presence of a third heart sound (S3 gallop) on auscultation.

Explanation: Loop diuretics are highly protein-bound, primarily to albumin. This binding is necessary for their delivery to the organic anion transporters in the proximal tubule, which secrete them into the tubular lumen to reach their site of action in the loop of Henle. In states of severe hypoalbuminemia (e.g., in advanced heart failure with hepatic congestion or cachexia), there is less albumin to carry the diuretic to the kidney, resulting in reduced drug delivery to the site of action and thus diuretic resistance. While low LVEF (B) is the underlying cause of the HF and high BNP (A) and an S3 (D) are signs of it, hypoalbuminemia is a direct pharmacokinetic reason for diuretic failure.

Question 13

Furosemide
Bumetanide
Spironolactone
Chlorthalidone (correct answer)

Question 14

A patient admitted for ADHF undergoes aggressive IV diuresis. After 48 hours, their weight is down 5 kg, JVP has normalized, and peripheral edema is nearly resolved. However, their serum creatinine has risen from a baseline of 1.4 mg/dL to 2.3 mg/dL. Which term best describes this clinical scenario?

Cardiorenal syndrome type 1
Intrinsic acute kidney injury from diuretic toxicity
Pseudo-worsening renal function (correct answer)
Diuretic braking phenomenon

Explanation: Pseudo-worsening renal function refers to a rise in serum creatinine that occurs in the context of successful and aggressive decongestion. It is thought to be a hemodynamic effect of volume removal rather than true tubular injury. In patients who are showing clear signs of decongestion (weight loss, decreased JVP), this rise in creatinine is often well-tolerated and may not be associated with poor outcomes. Cardiorenal syndrome type 1 (A) is AKI caused by worsening cardiac function, but here cardiac function is improving (decongestion). Intrinsic AKI (B) implies tubular damage, which is less likely. Diuretic braking (D) is a form of diuretic resistance, not a term for the rise in creatinine.

Question 15

Administer a one-time dose of intravenous (IV) furosemide 80 mg in the clinic.
Increase the oral furosemide dose to 80 mg twice daily and follow up in 2-3 days. (correct answer)
Add oral metolazone 2.5 mg daily to the current furosemide dose.
Switch from oral furosemide to an equivalent oral dose of bumetanide.

Question 16

Hydrochlorothiazide
Furosemide (correct answer)
Spironolactone
Chlorthalidone

Question 17

total cumulative dose of furosemide administered during the admission.
co-administration of a beta-blocker, such as carvedilol.
rate of intravenous infusion of the furosemide dose. (correct answer)
synergistic effect with a concurrently administered ACE inhibitor.

Question 18

40 mg daily
80 mg daily
120 mg daily
160 mg daily (correct answer)

Question 19

Administer a 500 mL bolus of normal saline.
Decrease the dose of carvedilol to improve blood pressure.
Temporarily hold or reduce the furosemide dose. (correct answer)
Discontinue the sacubitril/valsartan due to worsening renal function.

Question 20

A patient with ADHF is on a continuous furosemide infusion. The goal is a net negative fluid balance of 1.5 L/day. After 24 hours, the recorded total intake is 1200 mL and the total urine output is 2500 mL. However, the patient's daily morning weight has increased by 0.5 kg.

What is the most likely reason for the discrepancy between the calculated net negative fluid balance and the measured weight gain?

The furosemide infusion is causing a non-natriuretic osmotic diuresis.
Significant unmeasured insensible fluid losses are occurring.
The recorded fluid intake is likely inaccurate and underestimated. (correct answer)
Fluid is rapidly shifting from the intravascular to the interstitial space.

Explanation: The calculated fluid balance is 1200 mL (in) - 2500 mL (out) = -1300 mL, or a 1.3 L net loss. This should correspond to a weight loss of approximately 1.3 kg. Instead, the patient gained 0.5 kg. This creates a discrepancy of 1.8 kg (1800 mL). Insensible losses (B) are outputs, which would make the actual weight loss even greater, worsening the discrepancy. A non-natriuretic diuresis (A) or third-spacing (D) do not account for a gain in total body weight. The most common and plausible explanation for a negative fluid balance on paper but a weight gain in reality is inaccurate recording, specifically under-recording of oral fluid intake (e.g., patient drinking from a water pitcher not being documented).